Combination Therapy works for PBC

Study concludes that triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult‐to‐treat PBC.  Read full study.  

OCA real world experience

Since OCA (Ocaliva) was approved in the US in 2016 and Canada in 2017, there have been several  studies to assess its effectiveness in PBC patients around the world.  Here

CaNAL Patient Registry Update

The Canadian Network for Autoimmune Liver disease (CaNAL) is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. This nationwide

Cholestasis-Associated Pruritus and Its Pruritogens

Jacqueline A. G. M. Langedijk, Ulrich H. Beuers and Ronald P. J. Oude Elferink* published March 9, 2021, frontiers in Medicine. “Cholestasis is the term for diminished or impaired bile

Prognostic Factors for Clinical Outcomes in Patients with PBC

This thesis, written by Dr. Carla Fiorella Murillo Perez was published January 2021.  The study uses a large and globally representative cohort of patients with long-term follow-up to study various